Free tool
FAERS Monitor: Camptosar
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020571 or its brand name (Camptosar, Irinotecan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
11,125
Serious
10,272
92% of reports
Hospitalization
4,488
Death reported
2,058
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea1,417
- off label use884
- nausea810
- vomiting713
- myelosuppression697
- death681
- disease progression575
- febrile neutropenia575
- neutropenia545
- fatigue487
- pyrexia443
- neuropathy peripheral432
- abdominal pain399
- asthenia395
- neoplasm progression371
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 391 |
| 2005 | 171 |
| 2006 | 151 |
| 2007 | 171 |
| 2008 | 271 |
| 2009 | 309 |
| 2010 | 411 |
| 2011 | 395 |
| 2012 | 576 |
| 2013 | 356 |
| 2014 | 239 |
| 2015 | 444 |
| 2016 | 332 |
| 2017 | 344 |
| 2018 | 425 |
| 2019 | 474 |
| 2020 | 544 |
| 2021 | 544 |
| 2022 | 856 |
| 2023 | 858 |
| 2024 | 1,044 |
| 2025 | 1,106 |
| 2026 | 713 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,034 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 697 | 37.3 | 34.7 | 24,144 |
| neoplasm progressionSignal | 371 | 20.4 | 18.4 | 6,758 |
| febrile neutropeniaSignal | 575 | 16.5 | 15.3 | 8,324 |
| disease progressionSignal | 575 | 9.2 | 8.5 | 4,213 |
| neuropathy peripheralSignal | 432 | 8.6 | 7.9 | 2,903 |
| neutropeniaSignal | 545 | 7.6 | 7.0 | 3,127 |
| diarrhoeaSignal | 1,417 | 4.2 | 4.0 | 3,494 |
| abdominal painSignal | 399 | 3.2 | 2.9 | 624 |
| vomitingSignal | 713 | 2.9 | 2.7 | 885 |
| pyrexiaSignal | 443 | 2.4 | 2.2 | 374 |
| asthenia | 395 | 2.0 | 1.8 | 196 |
| nausea | 810 | 1.9 | 1.8 | 379 |
| off label use | 884 | 1.9 | 1.8 | 398 |
| death | 681 | 1.5 | 1.4 | 116 |
| fatigue | 487 | 1.2 | 1.1 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.